1,2-噻唑-4-甲酸甲酯 | 56133-37-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1,2-噻唑-4-甲酸甲酯
• 英文名称: methyl 1,2-thiazole-4-carboxylate
• 英文别名: Methyl isothiazole-4-carboxylate
• CAS: 56133-37-0
• 化学式: C₅H₅NO₂S
• 分子量: 143.166
• InChiKey: YELIYGBMHIGZIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,2-噻唑-4-甲酸甲酯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以71%的产率得到1,2-噻唑-4-基甲醇
  参考文献：
  名称：

  [EN] RESORCINOL N-ARYL AMIDE COMPOUNDS, FOR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS
  [FR] COMPOSÉS DE RÉSORCINOL N-ARYLAMIDE DESTINÉS À ÊTRE UTILISÉS COMME INHIBITEURS DE PYRUVATE DÉSHYDROGÉNASE KINASE

  摘要：

  一种具有以下结构的化合物：或其药用可接受的盐，其中：Y为–CONR1-或可选择地取代的芳基或可选择地取代的杂芳基；R1为H、Cl、F、CH3或CF3；每个R4独立地为H、CH3或F；R5为H或CH3；每个R2和R6独立地为(Alk)n-Rn-(Alk)n-Rn-(Alk)n-X；该发明的化合物可用作间苯二酚N-芳基酰胺（NAA）化合物，适用于用作PDK抑制剂，例如用于抑制癌细胞增殖。

  公开号：

  WO2015040425A1
• 作为产物：
  描述：

  甲醇 、 4-羧基异噻唑 在 氯化亚砜 作用下， 反应 2.0h， 以99%的产率得到1,2-噻唑-4-甲酸甲酯
  参考文献：
  名称：

  [EN] INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF
  [FR] INHIBITEURS DE FACTEURS DU COMPLÉMENT ET LEURS UTILISATIONS

  摘要：

  揭示了式I和II的化合物及其药用盐。还披露了使用此处披露的化合物治疗神经退行性疾病、炎症性疾病、自身免疫疾病、眼科疾病或代谢性疾病的方法。

  公开号：

  WO2022020244A1

文献信息

• [EN] RESORCINOL N-ARYL AMIDE COMPOUNDS, FOR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS<br/>[FR] COMPOSÉS DE RÉSORCINOL N-ARYLAMIDE DESTINÉS À ÊTRE UTILISÉS COMME INHIBITEURS DE PYRUVATE DÉSHYDROGÉNASE KINASE
  申请人：VERNALIS R & D LTD

  公开号：WO2015040425A1

  公开（公告）日：2015-03-26

  A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: Y is –CONR1- or optionally substituted arylene or optionally substituted heteroarylene; R1 is H, Cl, F, CH3 or CF3; 10 each R4 is independently H, CH3 or F; R5 is H or CH3; and each R2 and R6 is independently (Alk)n-Rn-(Alk)n-Rn-(Alk)n-X; The compounds of the invention are useful as resorcinol N-aryl amide (NAA) compounds, which are suitable for use as PDK inhibitors, for example for 15 inhibition of cancer cell proliferation.

  一种具有以下结构的化合物：或其药用可接受的盐，其中：Y为–CONR1-或可选择地取代的芳基或可选择地取代的杂芳基；R1为H、Cl、F、CH3或CF3；每个R4独立地为H、CH3或F；R5为H或CH3；每个R2和R6独立地为(Alk)n-Rn-(Alk)n-Rn-(Alk)n-X；该发明的化合物可用作间苯二酚N-芳基酰胺（NAA）化合物，适用于用作PDK抑制剂，例如用于抑制癌细胞增殖。
• 613. Isothiazole: a new mononuclear heterocyclic system
  作者：A. Adams、R. Slack

  DOI：10.1039/jr9590003061

  日期：——
• Solvolysis of isothiazole analogs of cumyl chloride. Determination of the Brown electrophilic substituent constants for isothiazole derivatives
  作者：Donald S. Noyce、Bonnie B. Sandel

  DOI：10.1021/jo00911a016

  日期：1975.11
• Inactivation of <i>O</i>⁶-Alkylguanine-DNA Alkyltransferase. 1. Novel <i>O</i>⁶-(Hetarylmethyl)guanines Having Basic Rings in the Side Chain
  作者：R. Stanley McElhinney、Dorothy J. Donnelly、Joan E. McCormick、Jane Kelly、Amanda J. Watson、Joseph A. Rafferty、Rhoderick H. Elder、Mark R. Middleton、Mark A. Willington、T. Brian H. McMurry、Geoffrey P. Margison

  DOI：10.1021/jm9708644

  日期：1998.12.1

  A number of novel guanine derivatives containing heterocyclic moieties at the O-6-position have been synthesized using a purine quaternary salt which reacts with alkoxides under mild conditions. Initially O-6-substituents were investigated in which the benzene ring of the known agent, O-6-benzylguanine, was replaced by unsubstituted heterocyclic rings. The ability of these agents to inactivate the DNA repair protein O-6-alkylguanine-DNA alkyltransferase (ATase), both as pure recombinant protein and in the human lymphoblastoid cell line Raji, has been compared with that of O-6-benzylguanine. The present paper focuses on O-6-substituents with basic rings, and under standard conditions several of them proved more effective than benzyl for inactivation of both recombinant and Raji ATase. Among the pyridine derivatives, the 2-picolyl compound 7 is not very active in contrast to the 3- and 4-picolyl compounds, and this influenced our choice of isomers of other basic ring systems for study. Since halogen substitution in the thiophene ring considerably increased the activity (17 versus 6), similar modifications in the pyridine series were examined. The more polar O-6-substituents in this study are on the whole compatible with the stereochemical requirements of the ATase protein, and their pharmacological properties may be valuable in subsequent in vivo investigations, particularly the thenyl (6), 5-thiazolylmethyl (12), 5-bromothenyl (17), and 2-chloro-4-picolyl (21) derivatives.
• [EN] INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF<br/>[FR] INHIBITEURS DE FACTEURS DU COMPLÉMENT ET LEURS UTILISATIONS
  申请人：ANNEXON INC

  公开号：WO2022020244A1

  公开（公告）日：2022-01-27

  Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.

  揭示了式I和II的化合物及其药用盐。还披露了使用此处披露的化合物治疗神经退行性疾病、炎症性疾病、自身免疫疾病、眼科疾病或代谢性疾病的方法。